Leerink Partnrs Analysts Lift Earnings Estimates for IRWD

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Stock analysts at Leerink Partnrs lifted their Q2 2025 earnings per share estimates for shares of Ironwood Pharmaceuticals in a research report issued to clients and investors on Wednesday, May 7th. Leerink Partnrs analyst F. Khurshid now forecasts that the biotechnology company will post earnings per share of ($0.05) for the quarter, up from their previous estimate of ($0.08). The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Leerink Partnrs also issued estimates for Ironwood Pharmaceuticals’ Q3 2025 earnings at $0.13 EPS and FY2026 earnings at $0.48 EPS.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.09). The company had revenue of $41.14 million during the quarter, compared to analysts’ expectations of $67.02 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%.

IRWD has been the subject of several other research reports. Leerink Partners decreased their target price on Ironwood Pharmaceuticals from $3.00 to $1.00 and set a “market perform” rating for the company in a research note on Monday, April 14th. StockNews.com upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. Wells Fargo & Company restated an “equal weight” rating and set a $1.00 target price (down previously from $7.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th. Citizens Jmp cut Ironwood Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, April 14th. Finally, Jefferies Financial Group restated a “hold” rating and set a $0.70 target price (down previously from $8.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th. Seven analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.78.

Ironwood Pharmaceuticals Stock Down 6.8%

IRWD stock opened at $0.68 on Monday. The business has a 50 day moving average price of $1.12 and a 200 day moving average price of $2.61. The stock has a market cap of $110.71 million, a price-to-earnings ratio of -22.81 and a beta of 0.37. Ironwood Pharmaceuticals has a fifty-two week low of $0.59 and a fifty-two week high of $7.11.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Pacer Advisors Inc. grew its position in shares of Ironwood Pharmaceuticals by 4.0% during the fourth quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock worth $51,967,000 after acquiring an additional 450,949 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Ironwood Pharmaceuticals by 4.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,983,240 shares of the biotechnology company’s stock worth $8,786,000 after acquiring an additional 78,969 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Ironwood Pharmaceuticals during the fourth quarter worth approximately $53,000. Amundi grew its position in shares of Ironwood Pharmaceuticals by 168.4% during the fourth quarter. Amundi now owns 61,979 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 38,889 shares during the last quarter. Finally, Los Angeles Capital Management LLC grew its position in shares of Ironwood Pharmaceuticals by 2,625.1% during the fourth quarter. Los Angeles Capital Management LLC now owns 331,700 shares of the biotechnology company’s stock worth $1,469,000 after acquiring an additional 319,528 shares during the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.